Sickle cell disease (SCD) changes the shape of a child's red blood cells. An inherited gene tells the body to make abnormal hemoglobin S. Under stress, low oxygen, cold, or dehydration, the cells stiffen into a sickle shape, get stuck in small blood vessels, block blood flow, and break apart faster than the body can replace them. The result is sudden pain, anemia, organ damage, and a high risk of dangerous infections. SCD affects roughly 100,000 people in the United States, and about 90% of newborns diagnosed with it are Black or African American.
Disease is not the same as trait
This matters before anything else. Sickle cell trait means a child inherited one sickle gene and one normal gene. Trait carriers are usually healthy and do not have the disease. Sickle cell disease means a child inherited a sickle gene from each parent, or a sickle gene plus another abnormal hemoglobin gene. About 1 in 13 Black babies is born with trait, but about 1 in 365 is born with the disease itself. If you are planning a pregnancy, our guide to trait, pregnancy, and family planning covers the carrier side.
Newborn screening catches it, but you confirm the type
Every US state screens newborns for SCD with the heel-prick blood test in the first days of life, so most children are identified before any symptoms appear. A screen-positive result is not the final answer. A second test (hemoglobin electrophoresis or DNA analysis) confirms the exact type, and the type drives the treatment plan. In a CDC study of more than 3,300 newborns with confirmed SCD across 11 states, about 57% had hemoglobin SS or sickle beta-zero thalassemia (together called sickle cell anemia, the most severe forms), about 28% had hemoglobin SC disease, and about 10% had sickle beta-plus thalassemia or another type. Ask your pediatrician for the written confirmed result and get your child into a pediatric hematology clinic, ideally before 2 months of age.
The daily essentials that save lives
SCD damages the spleen early in childhood, stripping away a major defense against bacterial infection. The routine that protects your child is not optional, and most of it is cheap and oral.
Penicillin twice a day. Children with sickle cell anemia should take prophylactic penicillin from infancy through at least age 5. It prevents life-threatening pneumococcal infection in the years when the spleen is failing. The standard dose is 125 mg twice daily under age 3 and 250 mg twice daily from age 3. If your child is allergic to penicillin, the clinic will substitute another antibiotic.
Every recommended vaccine, on time. Children with SCD need the full childhood schedule plus the pneumococcal and meningococcal vaccines, which protect against the bacteria a damaged spleen can no longer fight. Do not skip or delay these.
Hydroxyurea. The 2014 National Heart, Lung, and Blood Institute guidelines recommend offering hydroxyurea to every infant with sickle cell anemia starting at about 9 months of age, regardless of how sick the child has been. In the BABY HUG trial, infants on daily liquid hydroxyurea had fewer pain episodes, less dactylitis (painful swelling of the hands and feet), less acute chest syndrome, and fewer hospital stays and transfusions than those on placebo. The drug raises protective fetal hemoglobin, which keeps red cells from sickling. It is a daily pill or liquid, with regular blood counts to adjust the dose.
Hydration and temperature. Dehydration, cold, and overheating all trigger sickling. Keep your child well hydrated, dress them warmly in cold weather, and avoid extreme temperature swings. Folic acid is also commonly prescribed to support red cell production.
Protecting the brain: transcranial Doppler screening
SCD is the most common cause of stroke in childhood, and the risk peaks between ages 2 and 9. The protection is a painless ultrasound called transcranial Doppler (TCD) that measures blood flow speed in the brain. In the landmark STOP trial, children with abnormal TCD readings who received regular blood transfusions had their stroke risk cut by more than 90% compared with children who did not. Every child with sickle cell anemia should have annual TCD screening starting at age 2. If your clinic has not scheduled it, ask why.
Pain crises, and the bias you may have to push back on
A vaso-occlusive pain crisis is the hallmark of SCD. It is real, severe, and it is treated with fluids and prompt pain medicine, including opioids when the pain is severe. Black patients with SCD are too often undertreated in emergency rooms and labeled drug-seeking. In a study of emergency department wait times, SCD patients waited about 50% longer for care than patients with a long-bone fracture, even after accounting for race and triage priority. The American Society of Hematology reported in 2025 that most people with SCD who arrived in pain were not triaged at the urgency their guidelines call for, and those triaged too low waited nearly three times as long for a first dose of pain medicine.
You can blunt this. Carry a letter from your child's hematologist that states the diagnosis, the home pain regimen, and the medicines that work, and ask whether the clinic keeps an individualized pain protocol on file. State the diagnosis and the last dose clearly at triage. If your child is in obvious distress and being made to wait, ask to speak with the charge nurse and ask that the hematology team be paged.
The treatment horizon, including a cure
Beyond the daily regimen, two paths can prevent complications: chronic blood transfusions, used to lower stroke risk and treat severe disease, and for some children a cure. The long-standing curative option is a bone marrow (stem cell) transplant from a matched donor, usually a healthy sibling, which most children do not have. In December 2023 the FDA approved the first two gene therapies for SCD, Casgevy and Lyfgenia, for patients age 12 and older. Both reprogram a patient's own stem cells so they no longer sickle, and in trials about 9 in 10 patients went a year or more without a severe pain crisis. They are not yet an option for young children, the treatment is intensive, and list prices run into the millions of dollars, so access is far from universal. Ask your hematologist what is realistic for your family and whether a clinical trial fits. Our report on the gene-therapy access gap explains who is reaching these cures and who is being left behind.
How to get care
Your child needs a pediatric hematologist and a pediatrician who treat SCD often, take it seriously, and answer your calls. A clinician who shares your child's background can change how heard you feel and how fast pain is believed. You can find a Black pediatrician or hematologist in our directory. Before each visit, write down your questions: the confirmed SCD type, whether hydroxyurea has been offered, when the next TCD screening is due, and a written pain and fever action plan you can hand to any ER.
Frequently asked questions
What is the difference between sickle cell disease and sickle cell trait? ▼
Sickle cell trait means a child inherited one sickle gene and one normal gene. Trait carriers are usually healthy and do not have the disease. Sickle cell disease means a child inherited an abnormal hemoglobin gene from each parent, so most of their red cells can sickle and cause pain, anemia, and organ damage. About 1 in 13 Black babies has trait; about 1 in 365 has the disease.
Why is a fever an emergency for a child with sickle cell disease? ▼
SCD damages the spleen in early childhood, and the spleen is a main defense against bacterial infection. A fever of 101F or higher can signal a bloodstream infection that becomes life-threatening within hours. The child needs blood cultures and IV antibiotics right away, so go to the ER immediately rather than waiting to see if the fever passes.
Should my child with sickle cell disease take hydroxyurea? ▼
National guidelines recommend offering hydroxyurea to every child with sickle cell anemia (HbSS or sickle beta-zero thalassemia) starting at about 9 months of age, whether or not they have been sick. In the BABY HUG trial it reduced pain episodes, acute chest syndrome, hospital stays, and transfusions. Discuss the daily dose and blood-count monitoring with your child's hematologist.
Is there a cure for sickle cell disease in children? ▼
A bone marrow (stem cell) transplant from a matched donor can cure SCD, but most children do not have a matched sibling donor. In December 2023 the FDA approved two gene therapies, Casgevy and Lyfgenia, for patients 12 and older. They are intensive, very expensive, and not yet available to young children. Ask your hematologist whether transplant, gene therapy, or a clinical trial fits your child.
What is transcranial Doppler screening and when does my child need it? ▼
Transcranial Doppler (TCD) is a painless ultrasound that measures blood-flow speed in the brain to find children at high risk of stroke. Children with sickle cell anemia should have it every year starting at age 2. Children flagged as high risk can have their stroke risk cut by more than 90% with regular transfusions, so ask your clinic to keep the screening on schedule.
